Martina Weise

3.7k total citations
39 papers, 2.4k citations indexed

About

Martina Weise is a scholar working on Immunology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Martina Weise has authored 39 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 13 papers in Molecular Biology and 12 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Martina Weise's work include Biosimilars and Bioanalytical Methods (18 papers), Pharmaceutical studies and practices (12 papers) and Sexual Differentiation and Disorders (6 papers). Martina Weise is often cited by papers focused on Biosimilars and Bioanalytical Methods (18 papers), Pharmaceutical studies and practices (12 papers) and Sexual Differentiation and Disorders (6 papers). Martina Weise collaborates with scholars based in Germany, United States and Finland. Martina Weise's co-authors include Jeffrey Baron, Kevin M. Barnes, Elena Wolff‐Holz, Graeme Eisenhofer, Deborah P. Merke, Rachel I. Gafni, Verónica Abad, Pekka Kurki, Christian K. Schneider and George P. Chrousos and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Martina Weise

39 papers receiving 2.3k citations

Peers

Countries citing papers authored by Martina Weise

Since Specialization

Citations

This map shows the geographic impact of Martina Weise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martina Weise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martina Weise more than expected).

Fields of papers citing papers by Martina Weise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martina Weise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martina Weise. The network helps show where Martina Weise may publish in the future.

Co-authorship network of co-authors of Martina Weise

This figure shows the co-authorship network connecting the top 25 collaborators of Martina Weise. A scholar is included among the top collaborators of Martina Weise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martina Weise. Martina Weise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Tailored Biosimilar Approach: Expectations and Requirements 2025 ·Drugs ·(unknown), Sean Barry, (unknown), Niklas Ekman, (unknown), (unknown), Jonathan R. A. Maier, Martina Weise, Andrea Laslop, (unknown), Ger van Zandbergen, (unknown)	4
2	Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars? 2023 ·BioDrugs ·(unknown), (unknown), Niklas Ekman, Sean Barry, (unknown), (unknown), Martina Weise, Elena Wolff‐Holz	13
3	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience 2022 ·BioDrugs ·Pekka Kurki, Hye‐Na Kang, Niklas Ekman, Ivana Knežević, Martina Weise, Elena Wolff‐Holz	21
4	Biosimilars in der EU: Bestandsaufnahme und neue Herausforderungen 2020 ·Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz ·Elena Wolff‐Holz, Martina Weise	3
5	Evolution of the EU Biosimilar Framework: Past and Future 2019 ·BioDrugs ·Elena Wolff‐Holz, (unknown), Camille Vleminckx, Martina Weise	84
6	From bioequivalence to biosimilars: How much do regulators dare? 2019 ·Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen ·Martina Weise	5
7	Interchangeability of Biosimilars: A European Perspective 2017 ·BioDrugs ·Pekka Kurki, Leon van Aerts, Elena Wolff‐Holz, Thijs J. Giezen, Venke Skibeli, Martina Weise	137
8	Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016 2016 ·Generics and Biosimilars Initiative Journal ·Vito Annese, C. Avendaño, Ferdinand C. Breedveld, Niklas Ekman, Thijs J. Giezen, Fernando Gomollón, Pekka Kurki, Tore K Kvien, Andrea Laslop, L. Puig, Robin Thorpe, Martina Weise, Elena Wolff‐Holz	12
9	European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene 2014 ·Neuromuscular Disorders ·Manuel Haas, (unknown), Pavel Balabanov, Tomas Salmonson, Serge Bakchine, (unknown), Martina Weise, (unknown), (unknown), (unknown), (unknown), Violeta Stoyanova‐Beninska, Hans L. Hillege	114
10	Reply to In support of the European Union biosimilar framework 2012 ·Nature Biotechnology ·(unknown), Christian K. Schneider, John-Joseph Borg, Falk Ehmann, Niklas Ekman, Esa Heinonen, (unknown), Marcel H. N. Hoefnagel, R. Martijn van der Plas, (unknown), (unknown), Robin Thorpe, (unknown), Asterios S. Tsiftsoglou, Camille Vleminckx, (unknown), (unknown), Martina Weise, (unknown)	4
11	Setting the stage for biosimilar monoclonal antibodies 2012 ·Nature Biotechnology ·Christian K. Schneider, Camille Vleminckx, Iordanis Gravanis, Falk Ehmann, Jean‐Hugues Trouvin, Martina Weise, Steffen Thirstrup	57
12	Current european regulatory perspectives on insulin analogues 2011 ·Diabetology & Metabolic Syndrome ·Harald Enzmann, Martina Weise	2
13	Adrenomedullary Function in Patients with Nonclassic Congenital Adrenal Hyperplasia 2010 ·Hormone and Metabolic Research ·Somya Verma, (unknown), Carol VanRyzin, Bart Drinkard, (unknown), Martina Weise, Graeme Eisenhofer, Deborah P. Merke	16
14	Metabolic Abnormalities and Cardiovascular Risk Factors in Children with Myositis 2009 ·The Journal of Pediatrics ·(unknown), Kristina I. Rother, Martina Weise, Alaa Ahmed, Frederick W. Miller, Lisa G. Rider	23
15	Patients with Classic Congenital Adrenal Hyperplasia Have Decreased Epinephrine Reserve and Defective Glucose Elevation in Response to High-Intensity Exercise 2004 ·The Journal of Clinical Endocrinology & Metabolism ·Martina Weise, (unknown), Bart Drinkard, (unknown), Evangelia Charmandari, (unknown), Graeme Eisenhofer, Jack A. Yanovski, George P. Chrousos, Deborah P. Merke	50
16	Stress Dose of Hydrocortisone Is Not Beneficial in Patients with Classic Congenital Adrenal Hyperplasia Undergoing Short-Term, High-Intensity Exercise 2004 ·The Journal of Clinical Endocrinology & Metabolism ·Martina Weise, Bart Drinkard, (unknown), (unknown), Graeme Eisenhofer, Evangelia Charmandari, George P. Chrousos, Deborah P. Merke	54
17	Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma 2002 ·The Journal of Clinical Endocrinology & Metabolism ·Martina Weise, Deborah P. Merke, Karel Pacák, McClellan M. Walther, Graeme Eisenhofer	62
18	Children with Classic Congenital Adrenal Hyperplasia Have Elevated Serum Leptin Concentrations and Insulin Resistance: Potential Clinical Implications 2002 ·The Journal of Clinical Endocrinology & Metabolism ·Evangelia Charmandari, Martina Weise, Stefan R. Bornstein, Graeme Eisenhofer, Margaret F. Keil, George P. Chrousos, Deborah P. Merke	122
19	Catch-Up Growth Is Associated with Delayed Senescence of the Growth Plate in Rabbits 2001 ·Pediatric Research ·Rachel I. Gafni, Martina Weise, (unknown), (unknown), Kevin M. Barnes, (unknown), Jeffrey Baron	90
20	Leptin Secretion in Cushing’s Syndrome: Preservation of Diurnal Rhythm and Absent Response to Corticotropin-Releasing Hormone 1999 ·The Journal of Clinical Endocrinology & Metabolism ·Martina Weise, Verónica Abad, Robert V. Considine, Lynnette K. Nieman, Kristina I. Rother	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact